130 related articles for article (PubMed ID: 8649865)
1. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells.
Pollock RE; Lang A; Luo J; El-Naggar AK; Yu D
Oncogene; 1996 May; 12(9):2035-9. PubMed ID: 8649865
[TBL] [Abstract][Full Text] [Related]
2. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.
Toguchida J; Yamaguchi T; Ritchie B; Beauchamp RL; Dayton SH; Herrera GE; Yamamuro T; Kotoura Y; Sasaki MS; Little JB
Cancer Res; 1992 Nov; 52(22):6194-9. PubMed ID: 1423262
[TBL] [Abstract][Full Text] [Related]
3. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.
Stapleton AM; Timme TL; Gousse AE; Li QF; Tobon AA; Kattan MW; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1997 Aug; 3(8):1389-97. PubMed ID: 9815823
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA
Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
Das P; Kotilingam D; Korchin B; Liu J; Yu D; Lazar AJ; Pollock RE; Lev D
Cancer; 2007 Jun; 109(11):2323-33. PubMed ID: 17429838
[TBL] [Abstract][Full Text] [Related]
8. Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations.
Mazoyer S; Lalle P; Moyret-Lalle C; Marçais C; Schraub S; Frappaz D; Sobol H; Ozturk M
Oncogene; 1994 Apr; 9(4):1237-9. PubMed ID: 8134127
[TBL] [Abstract][Full Text] [Related]
9. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the p53 gene in postradiation sarcoma.
Nakanishi H; Tomita Y; Myoui A; Yoshikawa H; Sakai K; Kato Y; Ochi T; Aozasa K
Lab Invest; 1998 Jun; 78(6):727-33. PubMed ID: 9645763
[TBL] [Abstract][Full Text] [Related]
11. p53 abnormalities in different subtypes of human sarcomas.
Andreassen A; Oyjord T; Hovig E; Holm R; Flørenes VA; Nesland JM; Myklebost O; Høie J; Bruland OS; Børresen AL
Cancer Res; 1993 Feb; 53(3):468-71. PubMed ID: 8425179
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control.
Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D
Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829
[TBL] [Abstract][Full Text] [Related]
13. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
14. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
15. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
16. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR
Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250
[TBL] [Abstract][Full Text] [Related]
17. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
18. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.
Thompson TC; Park SH; Timme TL; Ren C; Eastham JA; Donehower LA; Bradley A; Kadmon D; Yang G
Oncogene; 1995 Mar; 10(5):869-79. PubMed ID: 7534899
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]